ImmuCell Corporation (IUL.F)
- Previous Close
4.6800 - Open
4.6800 - Bid 4.6400 x 300000
- Ask 4.8200 x 300000
- Day's Range
4.6800 - 4.6800 - 52 Week Range
4.0600 - 5.4000 - Volume
60 - Avg. Volume
27 - Market Cap (intraday)
36.688M - Beta (5Y Monthly) 0.60
- PE Ratio (TTM)
-- - EPS (TTM)
-0.7000 - Earnings Date May 9, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
immucell.comRecent News: IUL.F
Performance Overview: IUL.F
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: IUL.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: IUL.F
Valuation Measures
Market Cap
36.69M
Enterprise Value
51.42M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.21
Price/Book (mrq)
1.55
Enterprise Value/Revenue
2.94
Enterprise Value/EBITDA
-19.95
Financial Highlights
Profitability and Income Statement
Profit Margin
-33.05%
Return on Assets (ttm)
-7.36%
Return on Equity (ttm)
-20.86%
Revenue (ttm)
17.47M
Net Income Avi to Common (ttm)
-5.77M
Diluted EPS (ttm)
-0.7000
Balance Sheet and Cash Flow
Total Cash (mrq)
978.74k
Total Debt/Equity (mrq)
66.78%
Levered Free Cash Flow (ttm)
-4.51M